ADMA vs HALO vs ALNY vs RARE vs FOLD

For growth investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus 19. 6% for ADMA Biologics, Inc. (ADMA). ADMA Biologics, Inc. (ADMA) offers the better valuation at 13. 6x trailing P/E (9. 7x forward), making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ADMA Biologics, Inc.

(ADMA) is the cheapest at 13. 6x versus Alnylam Pharmaceuticals, Inc. at 126. 6x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +389. 2%, compared to -76. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: HALO returned +559. 7% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 51β versus Ultragenyx Pharmaceutical Inc. 's 1. 36β — meaning RARE is approximately 166% more volatile than HALO relative to the S&P 500. On balance sheet safety, ADMA Biologics, Inc. (ADMA) carries a lower debt/equity ratio of 17% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.

(ALNY) is pulling ahead at 65. 2% versus 19. 6% for ADMA Biologics, Inc. (ADMA). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -79. 5% for RARE. At the gross margin level — before operating expenses — FOLD leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 0x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 32. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADMA: 157. 0% to $21. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +559. 7% 10Y return). Both have compounded well over 10 years (HALO: +559. 7%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.